A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

← catalyst calendar

NCT07306832 · readout ≤ 620 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

18estimated

Sites

Countries

Australia, France, Italy +3

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-20

actual

When the study began enrolling

Primary completion

Apr 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2030

estimated

The whole study's end, after follow-up

First posted

2025-12-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Acute Myeloid Leukemia

Intervention

Drug: Pivekimab Sunirine

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation

measured Up to Approximately 24 Months

Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC)